REG - Cizzle Biotechnology - Patent Granted in Canada

Cizzle Biotechnology HoldingsAnnouncement

04/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260204:nRSD6042Ra&default-theme=true

RNS Number : 6042R  Cizzle Biotechnology Holdings PLC  04 February 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR")

 

4 February 2026

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Patent Granted in Canada

 

Cizzle Biotechnology, the UK-based developer of diagnostic tests for
early-stage cancer, is pleased to announce that patent applications that claim
protection for methods that measure the CIZ1B lung cancer biomarker have been
granted by the Canadian intellectual property office. The Company has a strong
patent portfolio and continues to seek additional protection in other key
markets globally. In addition to its existing patent coverage in the USA, a
further application is likely to be granted by the United States patent and
trademark office in due course.

 

The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant'
concerns a two-step test format developed by Cizzle at the University of York.
This test format is licensed to Cizzle Bio Inc ("BIO") for use in North
America and the Caribbean and these new patents will strengthen BIO's position
in commercialising the Company's innovative and proprietary technology.

 

Background

 

The discovery and development of the CIZ1B biomarker test is the product of
work by Professor Dawn Coverley, the Company's founder and CSO, and her
research team at the University of York. Initially supported by both UK
Research and Industry and Charity sector research grants it has been the
ambition to translate the laboratory findings into products that benefit
future cancer patients in the UK, and elsewhere around the world.

 

Cizzle Biotechnology's patent portfolio and technology know-how enhances the
Company's ability to deliver it's global commercial strategy to licence
globally its proprietary test for the CIZ1B biomarker for use in the early
detection of lung cancer. The Company's first licence agreement with BIO for
North America and the Caribbean, has led to partnerships between BIO and
specialist clinical laboratories and hospitals, to enable market penetration
that makes the test available to as many clinicians and patients as possible.

 

Cizzle Biotechnology also has been granted patent protection from the European
Patent Office and is now focussed on securing partnerships with accredited
facilities in the UK and Europe including the NHS.

 

This aligns well with the current NHS cancer plan which aims to dramatically
improve cancer survival by increasing the proportion of cancers diagnosed at
stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier
diagnosis is expected to save 55,000 additional lives per year by 2028. The
plan focuses on improving access to diagnosis and treatment, raising awareness
of cancer symptoms, and increasing the number of cancers identified through
screening, including personalised and risk-stratified approaches.

 

Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology,
said:

 

"The granted patents that cover the specific test format that we are taking to
market with our partners in North America and elsewhere will protect the
Company's offering and add an additional level of security for our
shareholders. They help to ensure that the Company's innovative and
commercially scalable CIZ1B biomarker test will bring benefit to cancer
patients, through the roll out of early detection programs."

 

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                               +44(0) 20 3328 5656
 John Depasquale / Piers Shimwell (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Staton

 

 

About Cizzle Biotechnology

 

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear
protein CIZ1, which is linked with the preservation of epigenetic integrity.
CIZ1B is highly associated with the presence of early-stage lung cancer and
can be measured in small quantities of blood. The company has developed CIZ1B
into a non-invasive, cost-effective blood test to help in the early detection
of lung cancer and has now entered commercial royalty-bearing arrangements to
license its proprietary technology, and into collaborations with centres of
excellence in cancer care. Cizzle was admitted to the Standard segment of the
main market of the London Stock Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFFFFEIVIIR



            Copyright 2019 Regulatory News Service, all rights reserved